Antwerp University Hospital (UZA) 2 articles published in JoVE Cancer Research Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis Maxim Le Compte1, Edgar Cardenas De La Hoz2, Sofía Peeters1, Evelien Smits1, Filip Lardon1, Geert Roeyen1,3, Steve Vanlanduit2, Hans Prenen1,4, Marc Peeters1,4, Abraham Lin1,5, Christophe Deben1 1Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, 2Industrial Vision Lab, University of Antwerp, 3Department of Hepatobiliary Transplantation and Endocrine Surgery, University Hospital Antwerp (UZA), 4Department of Oncology, University Hospital Antwerp (UZA), 5Plasma Lab for Applications in Sustainability and Medicine ANTwerp (PLASMANT), University of Antwerp This protocol describes a semi-automated method for medium- to high-throughput organoid drug screenings and microscope-agnostic, automated image analysis software to quantify and visualize multiparametric, single-organoid drug responses to capture intratumor heterogeneity. Medicine Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool Marco Giallombardo*1,2, Jorge Chacártegui Borrás*2,3, Marta Castiglia4, Nele Van Der Steen3, Inge Mertens5,6, Patrick Pauwels7,3, Marc Peeters8,3, Christian Rolfo2,3 1Department of Biopathology and Medical Biotechnology, Section of Biology and Genetics, University of Palermo, 2Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital (UZA), 3Center for Oncological Research (CORE), Antwerp University, 4Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 5Flemish Institute for Technological Research (VITO), 6CORE, Campus Groenenborger, Antwerp University, 7Molecular Pathology, Pathology Department, Antwerp University Hospital (UZA), 8Oncology Department, Antwerp University Hospital (UZA) This protocol describes the feasibility to perform miRNA profiling in exosomes, released in plasma of NSCLC patients, through a commercial exosome isolation kit with Proteinase K and RNAse treatments, in order to avoid circulating miRNAs contamination and evaluate their biomarker features in NSCLC.
